SCHEDULE: OrbiMed Discloses Stake in Yarrow Bioscience

OrbiMed Advisors LLC and affiliated entities have filed a Schedule 13D, disclosing beneficial ownership of approximately 9.97% of Yarrow Bioscience, Inc. common stock following a merger.

Summary

• OrbiMed Advisors LLC and its affiliates (OrbiMed Capital GP X LLC, OrbiMed Capital GP X, LP, and OrbiMed Genesis GP LLC) have filed a Schedule 13D, indicating a change in beneficial ownership of Yarrow Bioscience, Inc. common stock.
• The filing follows a merger on July 27, 2026, where a subsidiary of VYNE Therapeutics Inc. merged with Yarrow Bioscience, Inc. (formerly Yarrow Bioscience Operating Company Corp.).
• OrbiMed Private Investments X, LP received 233,019 shares and warrants for 4,084,827 shares, while OrbiMed Genesis Master Fund, L.P. received 33,287 shares and warrants for 583,545 shares.
• The total beneficial ownership reported by OrbiMed Advisors LLC is 266,306 shares, representing approximately 9.97% of the issued and outstanding common stock.
• The warrants have an exercise limitation (the 'Blocker') preventing beneficial ownership from exceeding 9.99% of the outstanding shares upon exercise.
• The reporting persons state their intent is for investment purposes and not to acquire control of the issuer's business.
• Mona Ashiya, a member of OrbiMed Advisors, is on the Board of Directors of Yarrow Bioscience, Inc.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing, primarily due to the nature of a Schedule 13D filing which indicates a change in beneficial ownership and potential investment strategy, rather than a company performance update.

Positives

• Significant investment by a reputable investment firm (OrbiMed) in Yarrow Bioscience, Inc.
• The filing indicates a strategic investment rather than an attempt to gain control, suggesting confidence in the company's long-term prospects.
• The presence of a board member from OrbiMed may bring valuable expertise and oversight to Yarrow Bioscience.

Negatives

• The filing is a Schedule 13D, which typically signifies a significant change in beneficial ownership and can sometimes precede activist investor actions or a change in strategic direction.
• The warrants are not currently exercisable beyond the 9.99% ownership limit, which may restrict future flexibility for OrbiMed.
• The lock-up agreement for Mona Ashiya restricts the sale of her shares for 180 trading days post-merger, potentially limiting immediate liquidity for her holdings.

Risks

• Potential for future changes in investment strategy by OrbiMed, which could involve acquiring more shares, disposing of shares, or influencing corporate actions.
• The exercise limitation on warrants could lead to complex adjustments or limitations on OrbiMed's potential future stake.
• The lock-up agreement for Mona Ashiya may create selling pressure once it expires, depending on market conditions and her intentions.

Future Outlook

The reporting persons state they intend to review their investment in the Issuer based on various factors and may take actions such as acquiring more shares or disposing of existing shares as they deem appropriate.

Management Comments

• The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities.
• Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time.
• If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions.
• Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions.

Industry Context

StockSavvy.ai notes that Schedule 13D filings by investment firms like OrbiMed often signal a significant shift in a company's shareholder landscape. This particular filing follows a merger, suggesting OrbiMed is taking a position in the newly structured entity, potentially seeing value in its post-merger operations or strategic direction.

Management Changes

Related Party Transactions

• Mona Ashiya, a member of OrbiMed Advisors, is on the Board of Directors of Yarrow Bioscience, Inc. and is obligated to transfer any securities received from stock options or awards to OrbiMed Advisors, which will then provide them to OPI X.

Stakeholder Impact

• Shareholders: The filing indicates a significant investor's stake, which could influence future stock performance and corporate strategy. The lock-up agreement may affect immediate selling pressure.
• Management: The presence of a board member from a major investor like OrbiMed may lead to increased scrutiny and collaboration on strategic decisions.
• Creditors: No direct impact mentioned, but any significant strategic shifts by OrbiMed could indirectly affect the company's financial stability.

Next Steps

• OrbiMed will continue to monitor Yarrow Bioscience, Inc.'s business, financial condition, and prospects.
• OrbiMed may acquire additional shares or securities of Yarrow Bioscience, Inc. in the future.
• OrbiMed may dispose of some or all of its current holdings in Yarrow Bioscience, Inc.

Key Dates

Recommendation

This filing is primarily a disclosure of beneficial ownership following a merger. While OrbiMed's investment is notable, there are no explicit financial results or forward-looking guidance that would strongly support a buy or sell recommendation. The intent is stated as investment, and future actions are contingent on market conditions and company performance, warranting a 'hold' stance pending further developments.

Keywords

Schedule 13D, OrbiMed Advisors, Yarrow Bioscience, Merger, Beneficial Ownership, Investment, Warrants, Blocker